Table 1

Consortia that address various stages of the value chain.

Collaboration nameManaging entityGoals and links to information
Biomanufacturing Research Program (BIOman)MIT Center for Biomedical InnovationManufacturing and quality control of biopharmaceuticals;
Biomarkers ConsortiumFNIHBiomarker identification and qualification;
Cancer CommonsSelf (nonprofit)Targeted treatments for patients with cancer;
Clinical Data Interchange Standards Consortium (CDISC)Self (nonprofit)Data standards and health care information;
Center for Medical Technology Policy (CMTP)Self (nonprofit)Clinical research standards, infrastructure, and coverage/reimbursement policy;
Clinical Trials Transformation Initiative (CTTI)DukeImprove clinical trial quality and efficiency;
Coalition Against Major Disease (CAMD)Critical Path InstituteTechnologies and tools in drug development for neurodegenerative diseases;
International Serious Adverse Event Consortium (iSAEC)Critical Path InstituteIdentify biomarkers that predict the risk of drug-related serious adverse events;
NEW Drug Development ParaDIGmS (NEWDIGS)MIT Center for Biomedical InnovationTransform global innovation system to more sustainably and reliably deliver new, better, affordable therapeutics to the right patients faster;
PROTECTInnovative Medicines InitiativeTools and methods for safety monitoring;
SAFE-TInnovative Medicines InitiativeIdentification of sensitive and predictive biomarkers of liver, kidney, and vascular system damages for use in clinical drug development;
Sage BionetworksSelf (nonprofit)Open-source molecular data gathering and analysis on human disease;